EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serum HE4 predicts progestin treatment response in endometrial cancer and atypical hyperplasia: A prognostic study

Chloe E Barr, Jamie C Sergeant, Heather J Agnew, James Bolton, Rhona J McVey, Emma J Crosbie iD

BJOG: An International Journal of Obstetrics & Gynaecology · 2023

DOI: 10.1111/1471-0528.17417 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJOG: An International Journal of Obstetrics & Gynaecology, 2023. Verfasst von Chloe E Barr und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynaecology, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UK. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Endometrial Hyperplasia, Precancerous Conditions, Intrauterine Devices, Medicated. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR Clinician Scientist, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust Clinical Research Fellowships.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate serum human epididymis‐4 (HE4) as a predictive biomarker of intrauterine progestin response in endometrial cancer and atypical endometrial hyperplasia (AEH).

Design

Prospective prognostic factor study.

Setting

Consecutive sample of women attending a tertiary gynaecological oncology centre in northwest England. Population Women with AEH or early‐stage, low‐grade endometrial cancer who were unfit for or declined primary surgical management.

Methods

A total of 76 women, 32 with AEH and 44 with endometrial cancer, were treated with a levonorgestrel intrauterine system (LNG‐IUS) for 12 months. Endometrial biopsies and imaging were performed to assess treatment response. Pretreatment serum HE4 was analysed by chemiluminescence immunoassay and diagnostic accuracy and logistic regression analyses were performed. Main Outcome Measures Progestin response at 12 months defined by histology and imaging.

Results

The median age and body mass index (BMI) of the final cohort were 52 years (interquartile range [IQR] 33–62 years) and 46 kg/m 2 (IQR 38–54 kg/m 2 ), respectively. Baseline serum HE4 was significantly higher in non‐responders than responders (119.2 pmol/L, IQR 94.0–208.4 pmol/L versus 71.8 pmol/L, IQR 56.1–84.2 pmol/L, p < 0.001). Older age (odds ratio [OR] 0.96, 95% CI 0.93–0.99, p = 0.02), baseline serum HE4 (OR 0.97, 95% CI 0.96–0.99, p = 0.001) and endometrial cancer histology (OR 0.22, 95% CI 0.72–0.68, p = 0.009) were associated with a lower likelihood of progestin treatment response. Serum HE4 remained independently associated with progestin treatment failure when adjusted for age and histology (adjusted hazard ratio 0.97, 95% CI 0.96–0.99, p = 0.008).

Conclusion

Serum HE4 shows promise as a predictive biomarker of progestin treatment response in endometrial cancer and AEH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsEndometrial HyperplasiaPrecancerous ConditionsIntrauterine Devices, MedicatedFemaleHumansAdultMiddle AgedProgestinsPrognosisHyperplasiaProspective StudiesEpididymisLevonorgestrelBiomarkers

Stichwörter der Autor:innen

HE4atypical endometrial hyperplasiabiomarkerendometrial cancerintrauterine progestinpredictionresponsetherapy

Substanzen

ProgestinsLevonorgestrelBiomarkers

Autor:innen und Institutionen

  • Department of Gynaecology, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
  • Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
  • Faculty of Biology, Medicine and Health, School of Health Sciences, Centre for Biostatistics, University of Manchester, Manchester, UK.
  • Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
  • Department of Histopathology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK.

ORCID-Profile: Emma J Crosbie

Förderung

  • NIHR Clinician Scientist
  • NIHR Manchester Biomedical Research Centre
  • Manchester University NHS Foundation Trust Clinical Research Fellowships
  • Manchester Biomedical Research Centre

Zitieren

APA

Barr, C. E., Sergeant, J. C., Agnew, H. J., Bolton, J., McVey, R. J., & Crosbie, E. J. (2023). Serum HE4 predicts progestin treatment response in endometrial cancer and atypical hyperplasia: A prognostic study. BJOG: An International Journal of Obstetrics & Gynaecology. https://doi.org/10.1111/1471-0528.17417

Vancouver

Barr CE, Sergeant JC, Agnew HJ, Bolton J, McVey RJ, Crosbie EJ. Serum HE4 predicts progestin treatment response in endometrial cancer and atypical hyperplasia: A prognostic study. BJOG: An International Journal of Obstetrics & Gynaecology. 2023. doi:10.1111/1471-0528.17417

BibTeX
@article{Barr2023,
  author = {Barr, Chloe E and Sergeant, Jamie C and Agnew, Heather J and Bolton, James and McVey, Rhona J and Crosbie, Emma J},
  title = {Serum HE4 predicts progestin treatment response in endometrial cancer and atypical hyperplasia: A prognostic study},
  journal = {BJOG: An International Journal of Obstetrics & Gynaecology},
  year = {2023},
  doi = {10.1111/1471-0528.17417}
}
Kostenlos starten →